Followers | 300 |
Posts | 68575 |
Boards Moderated | 4 |
Alias Born | 02/16/2008 |
![](https://investorshub.advfn.com/uicon/119680.png?cb=1635787235)
Thursday, May 11, 2023 7:49:45 PM
Inflammatory bowel disease (IBD) is a term for two conditions – Crohn's disease and ulcerative colitis – that are characterized by chronic inflammation of the gastrointestinal tract.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.
For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
https://www.prnewswire.com/news-releases/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease-301818552.html
Multi-year partnership with AMGN https://www.prnewswire.com/news-releases/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease-301818552.html
Per the terms, TCRX will receive $30M upfront in addition to preclinical, clinical, regulatory, and commercial milestones worth over $500M and tiered single-digit royalties. "TScan's platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs," Raymond Deshaies, AMGN's SVP of Global Research, said.
![Bullish](/static/images/ih2-bull.png)
Recent TCRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:20:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:20:04 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/14/2024 08:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:15:02 AM
- TScan Therapeutics Announces Updates to its Board of Directors • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:30:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:15:25 AM
- TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:34 PM
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares • GlobeNewswire Inc. • 04/24/2024 03:03:30 PM
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting • GlobeNewswire Inc. • 04/22/2024 09:01:23 PM
- TScan Therapeutics Announces Closing of Upsized Public Offering • GlobeNewswire Inc. • 04/19/2024 02:05:23 PM
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering • GlobeNewswire Inc. • 04/17/2024 04:30:57 AM
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering • GlobeNewswire Inc. • 04/16/2024 08:25:22 PM
- TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities • GlobeNewswire Inc. • 04/16/2024 08:01:00 PM
- TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/06/2024 09:11:41 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:05:39 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 12:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:15:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:41 PM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM